Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Inventory: 2017-2025

Historic Inventory for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $9.5 million.

  • Puma Biotechnology's Inventory rose 254.51% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 254.51%. This contributed to the annual value of $8.7 million for FY2024, which is 23.22% up from last year.
  • Latest data reveals that Puma Biotechnology reported Inventory of $9.5 million as of Q3 2025, which was up 10.30% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Inventory peaked at $9.5 million during Q3 2025, and registered a low of $2.7 million during Q3 2024.
  • Moreover, its 3-year median value for Inventory was $7.6 million (2023), whereas its average is $7.1 million.
  • Per our database at Business Quant, Puma Biotechnology's Inventory slumped by 52.93% in 2024 and then skyrocketed by 254.51% in 2025.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Inventory stood at $7.1 million in 2021, then slumped by 36.33% to $4.5 million in 2022, then spiked by 56.43% to $7.1 million in 2023, then grew by 23.22% to $8.7 million in 2024, then skyrocketed by 254.51% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, $8.6 million for Q2 2025, and $8.8 million during Q1 2025.